| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
CytomX Therapeutics Inc (NASDAQ: CTMX)
CTMX Technical Analysis
5
| As on 9th Jun 2023 CTMX STOCK Price closed @ 1.68 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.34 & Strong Sell for SHORT-TERM with Stoploss of 4.18 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CTMXSTOCK Price
| Open | 1.75 | Change | Price | % |
| High | 1.77 | 1 Day | -0.06 | -3.45 |
| Low | 1.67 | 1 Week | -0.03 | -1.75 |
| Close | 1.68 | 1 Month | 0.09 | 5.66 |
| Volume | 205300 | 1 Year | -2.19 | -56.59 |
| 52 Week High 6.45 | 52 Week Low 1.19 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CTMX Daily Charts |
CTMX Intraday Charts |
Whats New @ Bazaartrend |
CTMX Free Analysis |
|
|
CTMX Important Levels Intraday
| RESISTANCE | 1.87 |
| RESISTANCE | 1.81 |
| RESISTANCE | 1.77 |
| RESISTANCE | 1.73 |
| SUPPORT | 1.63 |
| SUPPORT | 1.59 |
| SUPPORT | 1.55 |
| SUPPORT | 1.49 |
CTMX Forecast May 2024
| 4th UP Forecast | 3.72 |
| 3rd UP Forecast | 3.07 |
| 2nd UP Forecast | 2.66 |
| 1st UP Forecast | 2.26 |
| 1st DOWN Forecast | 1.1 |
| 2nd DOWN Forecast | 0.7 |
| 3rd DOWN Forecast | 0.29 |
| 4th DOWN Forecast | -0.36 |
CTMX Weekly Forecast
| 4th UP Forecast | 2.76 |
| 3rd UP Forecast | 2.41 |
| 2nd UP Forecast | 2.20 |
| 1st UP Forecast | 1.99 |
| 1st DOWN Forecast | 1.37 |
| 2nd DOWN Forecast | 1.16 |
| 3rd DOWN Forecast | 0.95 |
| 4th DOWN Forecast | 0.60 |
CTMX Forecast2024
| 4th UP Forecast | 8.54 |
| 3rd UP Forecast | 6.34 |
| 2nd UP Forecast | 4.98 |
| 1st UP Forecast | 3.62 |
| 1st DOWN Forecast | -0.26 |
| 2nd DOWN Forecast | -1.62 |
| 3rd DOWN Forecast | -2.98 |
| 4th DOWN Forecast | -5.18 |
CytomX Therapeutics Inc ( NASDAQ USA Symbol : CTMX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CTMX Business Profile
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Address: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service